Table 2 Univariate analysis of UAS usage in patients with multiple kidney stones (≥ 2)
From: The dilemma of 12/14F ureteral access sheath (UAS) usage: a case control study
Total | UAS | No UAS | p value | Test | ||
|---|---|---|---|---|---|---|
General characteristics | Number of cases with multiple kidney stones (≥ 2) | 147 | 71 | 76 | ||
Gender (male/female) | 100/47 | 45/26 | 55/21 | 0.3218 | Chi2 | |
Side (Right/Left) | 58/89 | 31/40 | 27/49 | 0.4011 | Chi2 | |
Median Age (IQR), years | 56 (41; 70) | 56 (39; 69) | 55 (45; 70) | 0.3199 | MWU | |
BMI (IQR) | 26 (24; 30) | 26 (24; 30) | 27 (24; 30) | 0.5150 | MWU | |
ASA > 2* | 30/136 (22.06%) | 17/64 (26.56%) | 13/72 (18.06%) | 0.3236 | Chi2 | |
Recurrent Stone Former | 74/147 (50.34%) | 40/71 (56.34%) | 34/76 (44.74%) | 0.2147 | Chi2 | |
Prestenting | 138/147 (93.88%) | 70/71 (98.59%) | 68/76 (89.47%) | 0.0500 | Chi2 | |
Positive preoperative urine culture** | 47/130 (36.15%) | 29/65 (44.61%) | 18/65 (27.69%) | 0.0679 | Chi2 | |
Antibiotic prophylaxis*** | 44/83 (53.01%) | 23/36 (63.89%) | 21/47 (44.68%) | 0.1296 | Chi2 | |
Stone characteristics | Concomitant Ureterolithiasis | 45/147 (30.61%) | 25/71 (35.21%) | 20/76 (26.32%) | 0.3220 | Chi2 |
Lower Pole Kidney Stone | 129/147 (87.76%) | 62/71 (87.32%) | 67/76 (88.16%) | 1 | Chi2 | |
Median Lower Pole Kidney Stone Diameter (IQR), mm | 5 (4; 8) | 5 (4; 8) | 6 (4; 8) | 0.8806 | MWU | |
Median Kidney Stone Max. Diameter (IQR), mm | 7 (5; 9) | 7 (5; 9) | 6 (5; 9) | 0.8928 | MWU | |
Mean HU (SD) | 855 (483) | 811 (459) | 905 (506) | 0.1502 | t-test | |
Operative characteristics | Mean IPA (SD), degrees | 52.62 (17.26) | 50.14 (17.13) | 54.91 (17.06) | 0.08612 | t-test |
Median IPA – preoperative imaging (IQR), degrees | 49 (41; 65) | 44 (40; 60) | 54 (43; 66) | 0.07342 | MWU | |
Safety Wire**** | 114/143 (79.72%) | 53/69 (76.81%) | 61/74 (82.43%) | 0.5305 | Chi2 | |
Preceding semirigid URS | 96/147 (65.31%) | 44/71 (61.97%) | 52/76 (68.42%) | 0.5173 | Chi2 | |
Stone Extraction with fURS | 139/147 (94.56%) | 70/71 (98.59%) | 69/76 (90.79%) | 0.08543 | Chi2 | |
Postoperative Stenting | 143/147 (97.29%) | 71/71 (100.00%) | 72/76 (94.74%) | 0.1463 | Chi2 | |
Median Fluoroscopy Time**** (IQR), s | 85 (54; 139) | 101 (65; 140) | 71 (41; 128) | 0.0188 | MWU | |
Median Operation Time (IQR), min | 92 (58; 118) | 101 (76; 128) | 77 (54; 104) | 0.0041 | MWU | |
Laser in Calyceal System | 97/147 (65.99%) | 43/71 (60.56%) | 54/76 (71.05%) | 0.2431 | Chi2 | |
Median Total Laser Energy (IQR), kJ | 1.24 (0.54; 2.41) | 1.27 (0.88; 2.41) | 1.04 (0.48; 2.35) | 0.2599 | MWU | |
Outcomes | LOS > 48 h | 28/147 (19.05%) | 17/71 (23.94%) | 11/76 (14.47%) | 0.2109 | Chi2 |
fURS Defect | 18/147 (12.24%) | 11/71 (15.49%) | 7/76 (9.21%) | 0.3631 | Chi2 | |
Clavien Dindo ≥ 2 | 16/147 (10.88%) | 10/71 (14.08%) | 6/76 (7.89%) | 0.3477 | Chi2 | |
Postoperative SIRS | 13/147 (8.84%) | 10/71 (14.08%) | 3/76 (3.95%) | 0.0611 | Chi2 | |
Stone-free status | 95/147 (64.63%) | 42/71 (59.15%) | 53/76 (69.74%) | 0.2427 | Chi2 |